

## **Accure Therapeutics appoints Dr. Rossella Medori as chief medical officer**

**Key addition of executive with unique track record in CNS therapeutics to lead regulatory and clinical development of innovative disease modifying drugs**

**Barcelona, Spain, January 26, 2021** - Accure Therapeutics, a private translational R&D engine at clinical stage in the Central Nervous System (CNS) field, today announces the appointment of Dr Rossella Medori as chief medical officer (CMO). Her appointment reinforces the company's capabilities in progressing drug candidates to clinical development.

Dr Medori brings over 30 years invaluable experience and skills - from her CNS translational expertise to in-depth knowledge of clinical development, acquired during her successful career in large and small pharma and biotech companies.

In her career to date, Dr Medori has held leadership roles at Biogen, Janssen Cilag-J&J, BMS, Lilly, Prexton and Affiris. Her work has been critical in supporting the closing of in- and out-licensing transactions and investor exits. Rossella brings extensive experience in the global clinical development of novel therapeutics, from early clinical translation to marketing authorisation and reimbursement activities for multi-billion dollar drugs such as Tecfidera® and Plegridy®. Dr Medori is a member of the American Academy of Neurology and the author of numerous publications on multiple sclerosis, Parkinson's disease, prion diseases and schizophrenia, among others. She has served as a neurology peer reviewer for medical literature and a global lecturer on advances in neurology and neurological research.

In her new role, Dr Medori will lead the progress of Accure Therapeutics' assets from the research stage into phase 2 clinical stage and beyond, whilst also supporting the search for additional assets. Her first priority is the successful completion of the clinical phase 2 program of the ACT-01 compound, Accure's most advanced asset, in multiple sclerosis and the related indication - acute optic neuritis, and anticipate further clinical and regulatory activities. In parallel, she will boost the development of the other drug candidates ACT-02 and ACT-03 to phase 1.

"We warmly welcome Rossella as CMO; with her strong development mindset Dr Medori is a key addition to our team. Using her experience and significant success in clinical development, she will further support our ambition to steadily develop valuable new CNS medications," said Laurent Nguyen, CEO of Accure Therapeutics.

"I'm thrilled to join such an experienced team at Accure Therapeutics and contribute to its endeavours. I truly believe in the ambition of the new R&D engine, dedicated to providing game-changing disease modifying drugs in CNS for numerous patients in need of treatment," said Dr. Rosella Medori, CMO of Accure Therapeutics.

CNS disorders are a leading cause of disability and deaths worldwide, with prevalence set to increase due to an aging population. The CNS pharmaceutical market exceeds \$80 billion (€73bn) per year and sustained growth is expected over the coming years.

**About Accure Therapeutics**

Accure Therapeutics is a private translational R&D engine at clinical stage in the Central Nervous System (CNS) field. Based in Barcelona (Spain), it was launched in 2020 with a Series A funding led by Alta Life Sciences Spain I and supported by the Centre for Technological and Industrial Development (CDTI). This European company with an international mindset boasts a unique portfolio of three new chemical entity programs pursuing innovative targets - with potential to accommodate others. Accure aims to develop new disease modifying drugs to treat serious conditions such as optic neuritis, multiple sclerosis, Parkinson's disease and epilepsy. With an experienced business and scientific team, Accure Therapeutics is one of the few companies that operate in an agnostic fashion on initial science to deliver cutting-edge drugs in CNS.

<https://accure.health/>

---

Media and analysts contact

**Andrew Lloyd & Associates**

Amanda Bown/ Juliette Schmitt

[amanda@ala.com](mailto:amanda@ala.com) / [juliette@ala.com](mailto:juliette@ala.com)

Tél. : +44 1273 675 100

@ALA\_Group

---